Whereas new agents (such ADCs) are already making a strong impact on overall survival and quality of life of HER2 BC patients in particular scenarios, successfully treating metastatic disease, in particular to the CNS, will be the toughest challenge in the near future. This evidence concerns the gene ERBB2 and metastatic neoplasm.